Cytochrome P450 Enzymes as Drug Targets in Human Disease

被引:13
|
作者
Guengerich, F. Peter [1 ,2 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, 638B Robinson Res Bldg, 2200 Pierce Ave, Nashville, TN 37232 USA
基金
美国国家卫生研究院;
关键词
LANOSTEROL 14-ALPHA-DEMETHYLASE CYP51; SYNTHASE CYP11B2 INHIBITORS; CUSHINGS-SYNDROME; DISCOVERY; ANTIFUNGAL; METABOLISM; MECHANISM; SCH-56592; KNOCKOUT; MOLECULE;
D O I
10.1124/dmd.123.001431
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the mention of cytochrome P450 (P450) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential, but in certain disease states, it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in use, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e.g., P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1.
引用
收藏
页码:493 / 497
页数:5
相关论文
共 50 条
  • [41] Inhibition and induction of human cytochrome P450 (CYP) enzymes
    Pelkonen, O
    Mäenpää, J
    Taavitsainen, P
    Rautio, A
    Raunio, H
    XENOBIOTICA, 1998, 28 (12) : 1203 - 1253
  • [42] STEREOSELECTIVE METABOLISM OF ONDANSETRON BY HUMAN CYTOCHROME P450 ENZYMES
    Li, Qiang
    Chen, Xiaoyan
    Zhong, Dafang
    Duan, Mingyu
    DRUG METABOLISM REVIEWS, 2008, 40 : 205 - 205
  • [43] Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
    Äbelö, A
    Andersson, TB
    Antonsson, M
    Naudot, AK
    Skånberg, I
    Weidolf, L
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (08) : 966 - 972
  • [44] The Oxidative Metabolism of Dimemorfan by Human Cytochrome P450 Enzymes
    Chou, Yueh-Ching
    Chung, Yu-Ting
    Liu, Tsung-Yun
    Wang, Szu-Yu
    Chau, Gar-Yang
    Chi, Chin-Wen
    Soucek, Pavel
    Krausz, Kristopher W.
    Gelboin, Harry V.
    Lee, Chen-Hsen
    Ueng, Yune-Fang
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (02) : 1063 - 1077
  • [45] Bioactivation of tamoxifen by recombinant human cytochrome P450 enzymes
    Notley, LM
    de Wolf, CJF
    Wunsch, RM
    Lancaster, RG
    Gillam, EMJ
    CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (05) : 614 - 622
  • [46] Developmental expression of cytochrome P450 enzymes in human liver
    Hakkola, J
    Tanaka, E
    Pelkonen, O
    PHARMACOLOGY & TOXICOLOGY, 1998, 82 (05): : 209 - 217
  • [47] Structural insights into understudied human cytochrome P450 enzymes
    Machalz, David
    Pach, Szymon
    Bermudez, Marcel
    Bureik, Matthias
    Wolber, Gerhard
    DRUG DISCOVERY TODAY, 2021, 26 (10) : 2456 - 2464
  • [48] In vitro stability of human recombinant cytochrome P450 enzymes
    Yang, Jiansong
    Tucker, Geoffrey T.
    Rostami-Hodjegan, Amin
    DRUG METABOLISM REVIEWS, 2006, 38 : 102 - 102
  • [49] Ethynyl flavones as inhibitors of human cytochrome P450 enzymes
    Taylor, Shannon F.
    Liu, Jiawang
    Dupart, Patrick
    Foroozesh, Maryam
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [50] Approaches to deorphanization of human and microbial cytochrome P450 enzymes
    Guengerich, F. Peter
    Tang, Zhongmei
    Cheng, Qian
    Salamanca-Pinzon, S. Giovanna
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2011, 1814 (01): : 139 - 145